Related Experiment Video

Updated: Mar 2, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.5K

Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in gastric cancer cells

Miao Tian1, Yu Chen2, Dan Tian3

  • 1Department of Gynaecology and Obstetrics, Second Hospital of Jilin University, Changchun, China.

Gene
|May 9, 2017
PubMed

Insights

Beclin1, an autophagy regulator, suppresses gastric cancer by interacting with LAPTM4B. This interaction inhibits LAPTM4B-mediated Epidermal growth factor receptor (EGFR) activation, thereby repressing tumor growth.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • Beclin1 is a crucial autophagy regulator and tumor suppressor.
  • Reduced Beclin1 expression is linked to various human cancers, including gastric cancer.
  • The precise mechanisms by which Beclin1 inhibits gastric cancer remain unclear.

Purpose of the Study:

  • To elucidate the mechanism of Beclin1's tumor-suppressive function in gastric cancer.
  • To investigate the interaction between Beclin1 and Lysosome-associated transmembrane protein 4β (LAPTM4B).
  • To determine how this interaction impacts cancer cell growth and signaling pathways.

Main Methods:

  • Proteomics analysis to identify Beclin1-interacting proteins.
  • Co-immunoprecipitation assays to confirm Beclin1-LAPTM4B interaction.
  • Western blotting and cell proliferation assays to assess the impact on EGFR signaling and cell growth.

Main Results:

  • Beclin1 was found to associate with LAPTM4B, a protein overexpressed in tumors.
  • Beclin1 binds to both N- and C-termini of LAPTM4B, independent of the Vps34 complex.
  • Beclin1 competes with Epidermal growth factor receptor (EGFR) for LAPTM4B binding, inhibiting LAPTM4B-mediated EGFR activation and gastric cancer cell proliferation.

Conclusions:

  • Beclin1 represses gastric cancer progression by disrupting the oncogenic functions of LAPTM4B.
  • Beclin1's interaction with LAPTM4B inhibits EGFR signaling, offering a potential therapeutic target for gastric cancer.

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.7K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K